Alphyn Biologics Private Investor Meeting - San Francisco

Dear Esteemed Investor,

You are exclusively invited to a Private Investor Briefing introducing Alphyn Biologics, Inc., a groundbreaking biotech company transforming the treatment of dermatological diseases.

📍 Fogo de Chão
201 3rd St Suite 100, San Francisco, CA
🗓 January 12, 2025 | 1 PM PST

Discover why Alphyn is poised to lead the $118 billion Atopic Dermatitis (AD) market with its Zabalafin Hydrogel, a revolutionary, multi-target drug platform. After Phase 2a trials, Zabalafin has outperformed competitors, reducing investment risk while paving the way for significant near-term returns.

• De-risked Investment: Proven clinical efficacy, with Phase 2b trials ready to accelerate toward market approval.
• Massive Market Potential: A first-mover in multi-target AD treatment, addressing an unmet need in immuno-inflammatory conditions.
• Rare Exit Opportunity: Join Alphyn as they near pivotal milestones, with comparable acquisitions in the AD space delivering 20x returns in 18 months.

Alphyn is raising the final $2 million of its Series B round, following $8 million already secured. Accredited investors can join with a $500,000 minimum or $25,000 via SPV, participating at a $57 million pre-money valuation.

Attendance is limited and by invitation only. Please RSVP promptly to confirm your place and receive a calendar invitation.

To secure your spot or request additional materials (executive summary, investment deck), email Skylar Rallison at srallison@opus8.com.

Don’t miss this chance to gain insider access to one of biotech’s most promising opportunities.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Thanks much and all the best,

The Opus8 Team

Host or Publisher Opus8 Private Events